Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An announcement from Procaps Group ( (PROC) ) is now available.
On January 29, 2025, Procaps Group appointed Ms. Melissa Angelini and Dr. Camilo Camacho as Interim Co-Chief Executive Officers following the resignation of Mr. Jose Antonio Toledo Vieira. The transition is unrelated to the ongoing independent investigation. Additionally, Procaps Group received notice from Nasdaq regarding the delisting of its shares due to non-compliance with financial reporting rules, effective February 4, 2025. The shares will trade on the OTC Expert Market, which is not expected to affect business operations or SEC reporting requirements.
More about Procaps Group
Procaps Group is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies, reaching more than 50 countries across five continents. With a direct presence in 13 countries in the Americas and nearly 5,000 employees, Procaps operates under a sustainable model, offering over-the-counter pharmaceutical products, prescription drugs, nutritional supplements, and high-potency clinical solutions.
YTD Price Performance: -31.76%
Average Trading Volume: 106,661
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $179.5M
For an in-depth examination of PROC stock, go to TipRanks’ Stock Analysis page.
